SD-1029

Confirm delete?

SD-1029

Zoom

Cat No: 21029

Biochemicals - Kinase Inhibitors

SD-1029 is a Janus kinase 2 (JAK2) inhibitor.{48790,48791} It inhibits autophosphorylation of recombinant JAK2 when used at concentrations of 30 and 100 μM and decreases levels of phosphorylated JAK2, but not JAK1 or Src, in MDA-MB-468 and paclitaxel-...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

9-(3,4-dichlorophenyl)-2,7-bis[(dimethylamino)methyl]-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-dione, dihydrobromide

Correlated keywords:

118372-38-6 SD1029 JAK 2 1 MDAMB468 MDAMB MB468 OVCAR 8TR 8 TR OVCAR8 SKOV 3TR SKOV3 IL6 STAT 3 BHK21 U2 OS SNU387 SNU398 Hep G2 Huh 7 GL 37

Product Overview:
SD-1029 is a Janus kinase 2 (JAK2) inhibitor.{48790,48791} It inhibits autophosphorylation of recombinant JAK2 when used at concentrations of 30 and 100 μM and decreases levels of phosphorylated JAK2, but not JAK1 or Src, in MDA-MB-468 and paclitaxel-resistant OVCAR8TR cells when used at a concentration of 10 μM.{48790} SD-1029 (10 μM) decreases levels of phosphorylated STAT3 in MDA-MB-468, MDA-BM-435, OVCAR8TR, and SKOV3TR cells and inhibits IL-6-induced nuclear translocation of STAT3 in BHK-21 and U2OS cells.{48790} It decreases the viability of and increases levels of cleaved caspase-3 in SNU-387, SNU-398, HepG2, and Huh7 hepatocellular carcinoma cells when used at a concentration of 10 μM.{48792} SD-1029 (100 and 1,000 nM) inhibits hepatitis A virus replication in GL37 cells.{48791}

Size	1 mg
Shipping	dry ice
CAS Number	118372-34-2
Molecular Formula	C₂₅H₃₀Cl₂N₂O₃ • 2HBr
SMILES	ClC1=C(Cl)C=CC(C2C3=C(CCC(CN(C)C)C3=O)OC4=C2C(C(CN(C)C)CC4)=O)=C1.Br.Br
Molecular Weight	639,3
Formulation	A solid
Purity	≥80% (mixture of isomers)
Custom Code	2903.99
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.